Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

By Zacks Investment ResearchStock MarketsJun 11, 2021 01:57AM ET
www.investing.com/analysis/gilead-gild-gets-fda-nod-for-label-expansion-of-epclusa-200585617
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
By Zacks Investment Research   |  Jun 11, 2021 01:57AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Gilead Sciences (NASDAQ:GILD), Inc. GILD announced that the FDA has approved a label expansion of its hepatitis C virus (HCV) drug, Epclusa.

The drug has now been approved for treating children as young as 3 years of age, regardless of HCV genotype or liver disease severity. The FDA approved a New Drug Application (NDA) for two strengths of an oral pellet formulation of Epclusa (sofosbuvir 200 mg/velpatasvir 50 mg and sofosbuvir 150 mg/velpatasvir 37.5 mg) developed for use by younger children who cannot swallow tablets. The recommended dosage of Epclusa in children aged 3 years and older is based on weight.

The new oral pellet formulation enables treatment in early childhood with pangenotypic, panfibrotic regimen.

The approval was based on data from a phase II, open-label clinical study that enrolled 41 children, aged 3 years to less than 6 years, to be treated with Epclusa for 12 weeks. At 12 weeks after treatment completion, Epclusa achieved a sustained virologic response (SVR12) or cure rate of 83% (34/41) among all patients, 88% (28/32) in children with HCV genotype 1, 50% (3/6) in children with HCV genotype 2, and 100% in children with HCV genotype 3 (2/2) and HCV genotype 4 (1/1) each. Of the seven patients who did not achieve a cure, all discontinued treatment within one to 20 days of starting treatment.

Gilead’s stock has gained 18.1% this year compared with the industry's gain of 1.9%.

Zacks Investment Research
Zacks Investment Research
Image Source: Zacks Investment Research

The company’s first-quarter results were disappointing as the HIV business was adversely impacted by the ongoing pandemic. Competition is stiff as well from the likes of GlaxoSmithKline (NYSE:GSK) GSK.

The COVID-19 pandemic is expected to adversely impact HCV treatment initiations and HIV new starts and switches. Gilead expects a more gradual recovery in COVID-related dynamics, starting the second quarter of 2021.

The company is looking to diversify its revenue base as the virology business faces challenges. Gilead recently expanded its collaboration with Novo Nordisk (NYSE:NVO) NVO in non-alcoholic steatohepatitis (“NASH”) with plans to launch a new phase IIb study for a triple combination regimen in NASH patients with cirrhosis.

Gilead currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector includes Repligen (NASDAQ:RGEN) Corp. RGEN, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Repligen’s earnings estimates for 2021 have increased to $2.21 from $1.91 in the past 90 days.

+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

Novo Nordisk AS (NVO): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Repligen Corporation (RGEN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
 

Related Articles

Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email